Skip to main content
. 2020 Aug 16;105(10):e3785–e3797. doi: 10.1210/clinem/dgaa526

Figure 2.

Figure 2.

Patient disposition for all patients screened for the CHIASMA OPTIMAL trial. AE, adverse event; OOC, oral octreotide capsules.